Overseeing NPs and PAs is one of the most important and most regulated aspects of medical directorship. Here is exactly what physician oversight of mid-level providers involves — supervision vs. collaboration, chart review requirements, and state-by-state considerations.
How Medical Directors Oversee Mid-Level Providers
Executive Summary: Overseeing nurse practitioners and physician assistants is one of the most important and most regulated aspects of medical directorship. The specific requirements vary significantly by state, but the core principles — availability, chart review, protocol oversight, and documentation — are consistent. This guide covers everything a medical director needs to know about NP and PA oversight.
Introduction
In most healthcare settings that employ NPs and PAs, the medical director is responsible for providing physician oversight of their clinical practice. This oversight is not just a professional courtesy — it is a legal requirement in most states, and the medical director is personally responsible for ensuring it is fulfilled.
Understanding exactly what oversight is required — and how to fulfill it effectively — is essential for any medical director who works with mid-level providers.
Supervision vs. Collaboration: The Legal Framework
The legal framework for physician oversight of NPs and PAs varies significantly by state:
Supervision States
In supervision states, the physician must provide active oversight of the NP or PA's clinical practice. Requirements typically include:
- Physician availability (on-site or by phone) during clinical hours
- Review of a specified percentage of charts (varies by state, typically 10–30%)
- Co-signature of certain orders or prescriptions
- Regular in-person meetings
Examples: Many states still require physician supervision for PAs, and some require it for NPs.
Collaboration States
In collaboration states, the physician and NP or PA have a formal collaborative practice agreement that defines the scope of their working relationship. Requirements typically include:
- A written collaborative practice agreement
- Regular chart review (frequency specified in the agreement or by state law)
- Physician availability for consultation
- Regular meetings to review clinical performance
Examples: Many states have moved from supervision to collaboration for NPs, particularly those with full practice authority.
Full Practice Authority States
In full practice authority states, NPs can practice independently without physician oversight. However:
- PAs still require physician supervision in most full practice authority states
- Many organizations still choose to have a medical director for quality, compliance, and credentialing purposes
- Payers may still require physician oversight for certain services
The Collaborative Practice Agreement
In collaboration states, the collaborative practice agreement (CPA) is the foundational document for the physician-NP relationship. A well-structured CPA includes:
Scope of practice. The specific clinical activities the NP is authorized to perform under the agreement.
Prescribing authority. The medications the NP is authorized to prescribe, including any restrictions on controlled substances.
Chart review requirements. The frequency and scope of chart review by the collaborating physician.
Availability requirements. How the physician will be available for consultation and the expected response time.
Meeting requirements. The frequency of in-person or virtual meetings between the physician and NP.
Termination provisions. How either party can terminate the agreement and the notice required.
Chart Review: The Core Oversight Mechanism
Chart review is the primary mechanism through which a medical director fulfills their oversight responsibilities for mid-level providers. Key considerations:
Frequency. State law or the collaborative practice agreement typically specifies the minimum frequency. Best practice is at least monthly.
Selection. Charts can be selected randomly, targeted to specific clinical areas or diagnoses, or focused on new or complex cases.
What to look for:
- Clinical decision-making quality
- Documentation completeness
- Appropriate prescribing (especially controlled substances)
- Protocol adherence
- Scope of practice compliance
Documentation. Document every chart review with date, charts reviewed, findings, and actions taken.
Availability for Consultation
The medical director must be genuinely available for consultation when NPs and PAs have clinical questions. This means:
- Being reachable during business hours
- Having a clear process for urgent after-hours consultation
- Responding to consultation requests promptly
- Documenting consultation calls
Unavailability is one of the most common grounds for board complaints against medical directors. Take this requirement seriously.
Addressing Performance Concerns
When chart review or other oversight activities reveal performance concerns, the medical director must address them directly:
- Provide specific, constructive feedback to the provider
- Document the concern and the feedback provided
- Follow up to ensure the concern has been addressed
- Escalate to formal performance management if the concern persists
Do not ignore performance concerns. They tend to get worse, not better.
State-by-State Considerations
The specific requirements for physician oversight of NPs and PAs vary significantly by state. Before accepting any medical director role that involves NP or PA oversight, verify:
- Whether the state requires supervision or collaboration for NPs
- Whether the state requires supervision or collaboration for PAs
- The specific chart review requirements
- The availability requirements
- Whether a written collaborative practice agreement is required
The Federation of State Medical Boards (FSMB) and the American Association of Nurse Practitioners (AANP) maintain resources on state-specific requirements.
Frequently Asked Questions
Q: Can I serve as the collaborating physician for NPs in multiple states simultaneously? A: Yes, but you need to comply with the requirements of each state. Multi-state oversight arrangements are common in telehealth settings.
Q: What is the difference between a supervising physician and a collaborating physician? A: The terms reflect the legal framework in the specific state. "Supervising physician" is used in supervision states; "collaborating physician" is used in collaboration states. The practical responsibilities are similar.
Q: Can I delegate chart review to a nurse manager or quality coordinator? A: You can have support staff assist with the logistics of chart review, but the clinical review itself must be done by the physician. You cannot delegate the clinical judgment component.
Q: What happens if an NP or PA I oversee makes a clinical error? A: Consult a healthcare attorney immediately. Document your oversight activities. Assess whether the error reflects a systemic problem with the provider's practice or an isolated incident. Take appropriate corrective action.
Key Takeaways
- Physician oversight of NPs and PAs is a legal requirement in most states, with specific requirements that vary by state
- The legal framework ranges from active supervision to collaborative practice to full practice authority
- The collaborative practice agreement is the foundational document for physician-NP collaboration
- Chart review is the primary oversight mechanism — document every review
- Genuine availability for consultation is a legal requirement — take it seriously
- Address performance concerns directly and document your response
Call to Action
Schedule a strategy session with AJ Pakpour to develop an oversight structure for your specific setting and state.
Continue Reading: The Complete Medical Directorship Resource Center | Chart Review Responsibilities for Medical Directors | Medical Director Liability: What You Need to Know
Explore Topics
Written by
AJ Pakpour
AJ Pakpour is a healthcare entrepreneur, Vice President of Doctor Staffers, founder of AmeraCell, and creator of The Business of Modern Medicine, with 25+ years of experience building and advising healthcare businesses.